

OncoTherapy Science, Inc.

JUNE 18, 2014

Announcement of the Phase I Clinical Trial activation of the out-licensed antibody
from the Consolidated Subsidiary of OncoTherapy

OncoTherapy Science, Inc. (President & CEO: Takuya Tsunoda; hereinafter, "OncoTherapy") announces that the Clinical Trial Application for the Phase I trial in Europe of KHK6640, an Anti-amyloid beta (A β) peptide antibody which was out-licensed from Immunas Pharma, Inc. (President & CEO: Takuya Tsunoda; hereinafter, "Immunas"; a consolidated subsidiary of OncoTherapy) to Kyowa Hakko Kirin, Ltd. (Head office: Chiyoda-ku, Tokyo, President and CEO: Nobuo Hanai, hereinafter "Kyowa Hakko Kirin"), was submitted by Kyowa Hakko Kirin and the application has been accepted by the regulatory authority of Belgium.

This Clinical Trial is conducted to confirm the safety and tolerability of this anti-A β peptide antibody in patients with prodromal/mild/moderate Alzheimer's disease.

This antibody is a monoclonal antibody which selectively binds to pathological aggregates of A β peptide. A β aggregates are thought to be the main cause of Alzheimer's disease, and this antibody is expected to inhibit the progression of the disease.

Immunas will receive a milestone payment for this Phase I trial activation from Kyowa Hakko Kirin in accordance with the License Agreement.